gsk_boronia_australia

GSK triple combo COPD therapy shows superiority in Phase III trials

pharmafile | June 20, 2016 | News story | Research and Development, Sales and Marketing COPD, GSK, phase III 

GlaxoSmithKline (LSE: GSK), along with Innoviva (NASDAQ: INVA), have presented positive top-line results from a pivotal Phase III trial for a triple combination therapy for chronic obstructive pulmonary disease (COPD).

The once-daily combination of fluticasone furoate/umedclidinium/vilanterol represented a treatment containing an inhaled corticosteroid, long-acting muscarinic antagonist and long-acting beta agonist. COPD is a more severe form of asthma that is characterised by obstruction to airflow that interferes with normal breathing. It is estimated it affects as many as 329 million people worldwide.

In the late-stage FULFIL trial, the treatment combo met its two co-primary endpoints, in demonstrating significant improvements in lung function and health-related quality of life compared with twice-daily Symbicort Turbohaler (budesonide/formoterol).

Dave Allen, head of respiratory R&D at GSK, says: “We are delighted with the outcome of the FULFIL study. Triple combination therapy is already a reality for many patients with COPD and is dispensed in multiple inhalers. By combining three medicines in a single inhaler we can offer a convenient, once-daily dosing option to patients while improving their symptoms.”

The findings from this trial are expected to support GSK’s plans for an EU regulatory submission of the closed triple combination therapy for COPD which is expected by the end of 2016. The company has also signalled intentions to submit a new drug application to the US Food and Drug Administration by the close of the year.

Sean Murray

Related Content

louis-reed-pwckf7l4-no-unsplash_5

GSK shares data from global shingles survey

GSK has announced data from its new global survey about shingles. The data suggests that …

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

testalize-me-0je8ynv4mis-unsplash

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …

Latest content